# Scienture Holdings (SCNX) — News

SCNX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/scnx/news

## Recent headlines

- [Scienture reports approximately $1.22 million in unaudited preliminary Q3 2026 revenue, achieving 256% sequential growth](https://www.ainvest.com/news/scienture-reports-approximately-1-22-million-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth-2610) — AInvest Wire, Oct 13, 2026
- [Scienture Holdings, Inc. announces reverse stock split](https://www.ainvest.com/news/scienture-holdings-announces-reverse-stock-split-2610) — AInvest Wire, Sep 30, 2026
- [Scienture - Rezenopy to be available in about 2,000 OTP clinics and addiction centers in U.S.](https://www.ainvest.com/news/scienture-rezenopy-2-000-otp-clinics-addiction-centers-2609) — AInvest Wire, Sep 22, 2026
  Scienture Holdings, Inc. (NASDAQ: SCNX) has expanded access to its FDA-approved naloxone product, REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, by securing placement in approximately 2,000 opioid treatment program (OTP) clinics and addiction centers across the United States. This development follows…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).